These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27098218)

  • 1. Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML.
    Gorkin L; Kantarjian H
    Nat Rev Clin Oncol; 2016 May; 13(5):270-2. PubMed ID: 27098218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular response in CML: where is the bar?
    Baccarani M; Soverini S
    Blood; 2014 Jul; 124(4):469-71. PubMed ID: 25061165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinase inhibitor therapy in CML: it's what's inside that counts.
    Eide CA; Druker BJ; O'Hare T
    Oncotarget; 2013 Sep; 4(9):1332-3. PubMed ID: 23934763
    [No Abstract]   [Full Text] [Related]  

  • 4. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
    Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond Gleevec--the next generation in CML.
    Fricker J
    Eur J Cancer; 2006 Feb; 42(3):275. PubMed ID: 16514710
    [No Abstract]   [Full Text] [Related]  

  • 8. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
    Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
    Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
    Kantarjian H; O'Brien S; Cortes J; Giles F; Shan J; Rios MB; Faderl S; Verstovsek S; Garcia-Manero G; Wierda W; Kornblau S; Ferrajoli A; Keating M; Talpaz M
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):68-75. PubMed ID: 14734453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
    Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of chronic myelogenous leukemia by using imatinib].
    Jinnai I
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1819-24. PubMed ID: 16223141
    [No Abstract]   [Full Text] [Related]  

  • 12. Looking beyond imatinib: next line of targeted drugs for CML shows promise.
    Hampton T
    JAMA; 2006 Jan; 295(4):369-70. PubMed ID: 16434621
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of the new patient with CML in chronic phase.
    Marin D
    Curr Hematol Malig Rep; 2013 Mar; 8(1):37-42. PubMed ID: 23381448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
    Murphy M; Close J; Lottenberg R; Rajasekhar A
    Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
    [No Abstract]   [Full Text] [Related]  

  • 15. Early prediction of a long-term outcome by neutrophil-FISH in patients with CML receiving imatinib mesylate.
    Takahashi N; Kameoka Y; Tagawa H; Saitoh H; Yoshioka T; Fujishima N; Kitabayashi A; Takahashi K; Hirokawa M; Sawada K
    Int J Hematol; 2010 Oct; 92(3):559-61. PubMed ID: 20838959
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib.
    Park MJ; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Jeong JW; Ahn JY; Park J
    Ann Lab Med; 2014 May; 34(3):247-51. PubMed ID: 24790915
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib mesylate in the treatment of chronic myelogenous leukemia.
    Borthakur G; Cortes JE
    Int J Hematol; 2004 Jun; 79(5):411-9. PubMed ID: 15239390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK; King RS
    Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
    [No Abstract]   [Full Text] [Related]  

  • 19. [Roles of the 2nd generation TKIs for CML].
    Matsumura I
    Rinsho Ketsueki; 2011 Oct; 52(10):1610-8. PubMed ID: 21971238
    [No Abstract]   [Full Text] [Related]  

  • 20. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
    Gruber FX; Ernst T; Porkka K; Engh RA; Mikkola I; Maier J; Lange T; Hochhaus A
    Leukemia; 2012 Jan; 26(1):172-7. PubMed ID: 21818112
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.